WTR Healthcare Happenings

GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders

Joe Brunetto

On the latest WTR Healthcare Happenings podcast episode, we welcomed Jan Eryk Umiastowski, CFO of GenSight Biologics (Euronext Paris: SIGHT), a late clinical-stage biopharma company based in Paris, France, primarily focused on developing and commercializing novel disease-modifying gene therapies aimed at reversing vision loss from severe neurodegenerative retinal diseases. He discusses GenSight's development pipeline, what's unique about  the company's approach to gene therapy and upcoming target milestones.